Veradermics, Inc (MANE) earnings date

NYSE · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 24 (last 4 releases)

Last 4 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026before open 41 8-K
Q2 FY2026Tue, Aug 11, 2026before open 42 8-K
Q1 FY2026Tue, May 12, 2026before open 42 8-K
Q4 FY2025Mon, Mar 30, 2026before open 89 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first oral treatment to receive FDA approval for pattern hair loss in nearly 30 years Company remains on track to deliver topline data from Phase 2/3 Study ‘306’ evaluating VDPHL01 in female pattern hair loss in 1H27 Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair " exhibit
Q3 FY2026 "The Company expects to report topline data in the first half of 2027." exhibit
Q2 FY2026 "Document Exhibit 99.1 Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female pattern hair loss, marking a milestone in the development of the potential first oral prescription treatment for women; topline readout anticipated in 1H27 VDPHL01 has th" exhibit
Q2 FY2026 "The Company expects to report topline data in the first half of 2027." exhibit
Q2 FY2026 "Phase 3 Study ‘304’; Topline Data Anticipated in 2H26: T opline data from Study ‘304’, a confirmatory Phase 3 trial evaluating the safety and efficacy of VDPHL01 in the treatment of male pattern hair loss, are expected in the second half of 2026." exhibit
Q2 FY2026 "Strengthened Balance Sheet: Veradermics raised approximately $472.0 million in aggregate gross proceeds in May 2026 through its follow-on offering and concurrent private placement subsequent to the initial public offering in February of 2026." exhibit
Q2 FY2026 "These proceeds, together with existing cash, cash equivalents and marketable securities, are expected to support Veradermics’ current operating plans into 2030, including multiple anticipated Phase 3 readouts and the potential commercial launch of VDPHL01, if approved." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MANE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MANE

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

MANE earnings date badge

HTML

<a href="https://veritasdata.dev/company/MANE/"><img src="https://veritasdata.dev/embed/MANE.svg" alt="MANE earnings date" width="240" height="56"></a>

Markdown

[![MANE earnings date](https://veritasdata.dev/embed/MANE.svg)](https://veritasdata.dev/company/MANE/)

Script

<script async src="https://veritasdata.dev/embed/MANE.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MANE"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.